BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 30891618)

  • 1. Clinical significance of circulatory microRNA-203 in serum as novel potential diagnostic marker for multiple myeloma.
    Gupta N; Kumar R; Seth T; Garg B; Sati HC; Sharma A
    J Cancer Res Clin Oncol; 2019 Jun; 145(6):1601-1611. PubMed ID: 30891618
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting of stromal versican by miR-144/199 inhibits multiple myeloma by downregulating FAK/STAT3 signalling.
    Gupta N; Kumar R; Seth T; Garg B; Sharma A
    RNA Biol; 2020 Jan; 17(1):98-111. PubMed ID: 31532704
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Versican and its associated molecules: potential diagnostic markers for multiple myeloma.
    Gupta N; Khan R; Kumar R; Kumar L; Sharma A
    Clin Chim Acta; 2015 Mar; 442():119-24. PubMed ID: 25623955
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of miR-144/199 promote myeloma pathogenesis via upregulation of versican and FAK/STAT3 signaling.
    Gupta N; Kumar R; Sharma A
    Mol Cell Biochem; 2021 Jun; 476(6):2551-2559. PubMed ID: 33649985
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Circulating Serum MicroRNA as Diagnostic Biomarkers for Multiple Myeloma].
    Xu YN; Xiao CR; Huang YD; Lu QY
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Apr; 25(2):471-475. PubMed ID: 28446295
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of a novel microRNA, miR-4449, as a potential blood based marker in multiple myeloma.
    Shen X; Ye Y; Qi J; Shi W; Wu X; Ni H; Cong H; Ju S
    Clin Chem Lab Med; 2017 May; 55(5):748-754. PubMed ID: 27155004
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Circulating miRNAs as diagnostic biomarkers for multiple myeloma and monoclonal gammopathy of undetermined significance.
    Li J; Zhang M; Wang C
    J Clin Lab Anal; 2020 Jun; 34(6):e23233. PubMed ID: 32039495
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low serum miR-19a expression as a novel poor prognostic indicator in multiple myeloma.
    Hao M; Zang M; Wendlandt E; Xu Y; An G; Gong D; Li F; Qi F; Zhang Y; Yang Y; Zhan F; Qiu L
    Int J Cancer; 2015 Apr; 136(8):1835-44. PubMed ID: 25220540
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Circulating Serum MicroRNA-130a as a Novel Putative Marker of Extramedullary Myeloma.
    Besse L; Sedlarikova L; Kryukov F; Nekvindova J; Radova L; Slaby O; Kuglik P; Almasi M; Penka M; Krejci M; Adam Z; Pour L; Sevcikova S; Hajek R
    PLoS One; 2015; 10(9):e0137294. PubMed ID: 26389804
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Circulating serum microRNAs as novel diagnostic and prognostic biomarkers for multiple myeloma and monoclonal gammopathy of undetermined significance.
    Kubiczkova L; Kryukov F; Slaby O; Dementyeva E; Jarkovsky J; Nekvindova J; Radova L; Greslikova H; Kuglik P; Vetesnikova E; Pour L; Adam Z; Sevcikova S; Hajek R
    Haematologica; 2014 Mar; 99(3):511-8. PubMed ID: 24241494
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Significance of Serum MicroRNAs in the Auxiliary Diagnosis of Non-Small Cell Lung Cancer.
    Shi GL; Chen Y; Sun Y; Yin YJ; Song CX
    Clin Lab; 2017 Jan; 63(1):133-140. PubMed ID: 28164492
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum high expression of miR-214 and miR-135b as novel predictor for myeloma bone disease development and prognosis.
    Hao M; Zang M; Zhao L; Deng S; Xu Y; Qi F; An G; Qin Y; Sui W; Li F; Yang W; Li Z; Yi S; Zou D; Zhan F; Qiu L
    Oncotarget; 2016 Apr; 7(15):19589-600. PubMed ID: 26995755
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of circulating microRNAs as diagnostic biomarkers for use in multiple myeloma.
    Jones CI; Zabolotskaya MV; King AJ; Stewart HJ; Horne GA; Chevassut TJ; Newbury SF
    Br J Cancer; 2012 Dec; 107(12):1987-96. PubMed ID: 23169280
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Circulating microRNA-133, microRNA-17 and microRNA-25 in serum and its potential diagnostic value in gastric cancer.
    ZiaSarabi P; Sorayayi S; Hesari A; Ghasemi F
    J Cell Biochem; 2019 Aug; 120(8):12376-12381. PubMed ID: 30861177
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of circulating miRNAs in multiple myeloma.
    Zhang J; Xiao X; Liu J
    Sci China Life Sci; 2015 Dec; 58(12):1262-9. PubMed ID: 26607481
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Downregulation of serum microRNA-205 as a potential diagnostic and prognostic biomarker for human glioma.
    Yue X; Lan F; Hu M; Pan Q; Wang Q; Wang J
    J Neurosurg; 2016 Jan; 124(1):122-8. PubMed ID: 26230475
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum exosomal microRNAs as novel biomarkers for multiple myeloma.
    Zhang ZY; Li YC; Geng CY; Zhou HX; Gao W; Chen WM
    Hematol Oncol; 2019 Oct; 37(4):409-417. PubMed ID: 31102419
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plasma MicroRNA-34a as a Potential Biomarker for Early Diagnosis of Esophageal Cancer.
    Lin Y; Lin Z; Fang Z; Li H; Zhi X; Zhang Z
    Clin Lab; 2019 Nov; 65(11):. PubMed ID: 31710448
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Potential value of circulatory microRNA122 gene expression as a prognostic and metastatic prediction marker for breast cancer.
    Saleh AA; Soliman SE; Habib MSE; Gohar SF; Abo-Zeid GS
    Mol Biol Rep; 2019 Jun; 46(3):2809-2818. PubMed ID: 30835039
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Circulating miR-20a and miR-26a as Biomarkers in Prostate Cancer.
    Mohammadi Torbati P; Asadi F; Fard-Esfahani P
    Asian Pac J Cancer Prev; 2019 May; 20(5):1453-1456. PubMed ID: 31127907
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.